Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 2/3 2Phase 1/2 2Phase NA 1Phase 3 1Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Multiple Myeloma 6Carcinoma, Hepatocellular 2Uveal Melanoma 1Prostatic Neoplasms 1Plasmacytoma 1Neoplasms, Plasma Cell 1Neoplasms 1Melanoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Carcinoma, Renal Cell 1Amyloidosis 1

Interventions

Sorafenib 26Nivolumab 21pembrolizumab 15Bevacizumab 14lenvatinib 12atezolizumab 9Cyclophosphamide 9Ipilimumab 8durvalumab 6camrelizumab 5apatinib 5Specimen Handling 5Radiosurgery 5tislelizumab 4fludarabine 4Immunotherapy, Adoptive 4Fluorouracil 4Doxorubicin 4tremelimumab 3toripalimab 3sintilimab 3regorafenib 3cabozantinib 3X-Rays 3Magnetic Resonance Spectroscopy 3Injections 3Everolimus 3Ethiodized Oil 3Erlotinib Hydrochloride 3tepotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Hepatocellular × Thalidomide × Clear all
NCT00971126 2016-05-04

Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)

National Health Research Institutes, Taiwan

Phase 1/2 Terminated
3 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00155272 2005-09-12

Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma

National Taiwan University Hospital

Phase 1/2 Unknown
19 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡